Disclosures for "Early-stage Parkinson’s Disease Experiences with a Week-long Dopaminergic Medication Washout"
-
Mr. Pazira has nothing to disclose.
-
Ms. Venditti has nothing to disclose.
-
Ms. Bonnet has nothing to disclose.
-
Dr. Schlundt has received personal compensation in the range of $0-$499 for serving as a Consultant for Advarra. The institution of Dr. Schlundt has received research support from NCI. The institution of Dr. Schlundt has received research support from NCI. The institution of Dr. Schlundt has received research support from NIH.
-
Dr. Charles has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Revance. Dr. Charles has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Iota. Dr. Charles has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Kyowa Kirin. Dr. Charles has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Ceraxis. Dr. Charles has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Aspen Neuroscience. Dr. Charles has stock in Arena Therapeutics. The institution of Dr. Charles has received research support from Pharma 2 B. The institution of Dr. Charles has received research support from Intec. The institution of Dr. Charles has received research support from Merz. The institution of Dr. Charles has received research support from Novartis. The institution of Dr. Charles has received research support from Aeon. The institution of Dr. Charles has received research support from Impax. The institution of Dr. Charles has received research support from AskBio. The institution of Dr. Charles has received research support from BlueRock. The institution of Dr. Charles has received research support from AbbVie. The institution of Dr. Charles has received research support from Ipsen.
-
Dr. Hacker has nothing to disclose.